A Retrospective, observational pharmacovigilance analysis of Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) indicated for renal cell carcinoma
Latest Information Update: 19 May 2021
At a glance
- Drugs Axitinib (Primary) ; Cabozantinib (Primary) ; Lenvatinib (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Gastric cancer; Liver cancer; Renal cell carcinoma; Thyroid cancer
- Focus Adverse reactions
- 19 May 2021 New trial record
- 10 May 2021 Results published in the Targeted Oncology.